HanAll Biopharma Reports First Quarter Results and Provides Business Update
- Written by PR Newswire
 |
- Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022
- HanAll made a strong start to 2023 with positive Phase 3 study results of anti-FcRn asset batoclimab for the treatment of generalized myasthenia gravis in China, setting a monumental milestone for anti-FcRn developers...
